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BACKGROUND/AIMS: We identified carnosinase-1 (CN-1) as risk-factor for diabetic 
nephropathy (DN). Carnosine, the substrate for CN-1, supposedly is a protective factor 
regarding diabetic complications. In this study, we hypothesized that carnosine administration 
to diabetic rats might protect the kidneys from glomerular apoptosis and podocyte loss.  
METHODS: We examined the effect of oral L-carnosine administration (1g/kg BW per day) 
on apoptosis, podocyte loss, oxidative stress, AGEs and hexosamine pathway in kidneys of 
streptozotocin-induced diabetic Wistar rats after 3 months of diabetes and treatment.  
RESULTS: Hyperglycemia significantly reduced endogenous kidney carnosine levels. In 
parallel, podocyte numbers significantly decreased (-21% compared to non-diabetics, 
p<0.05), apoptotic glomerular cells numbers increased (32%, compared to non-diabetic, 
p<0.05) and protein levels of bax and cytochrome c increased (175% and 117%). Carnosine 
treatment restored carnosine kidney levels, prevented podocytes loss (+23% compared to 
diabetic, p<0.05), restrained glomerular apoptosis (-34% compared to diabetic; p<0.05) and 
reduced expression of bax and cytochrome c (-63% and -54% compared to diabetics, both 
p<0.05). In kidneys of all diabetic animals, levels of ROS, AGEs and GlcNAc-modified 
proteins were increased.  
CONCLUSION: By inhibition of pro-apoptotic signaling and independent of biochemical 









Diabetic kidney disease (DKD) is a frequent complication of both diabetes mellitus type 1, 
and type 2. About one third of patients with DKD will progress to overt diabetic nephropathy 
(DN) within 5-15 years.  ROS production, non-enzymatic glycosylation and an increased flux 
through the hexosamine pathway are important biochemical changes in hyperglycaemic 
patients and are causally linked to the development of DN (25-27). Early in the development 
of DN, these biochemical changes cause apoptosis of different glomerular cells (17, 218, 
219), thereby promoting the development of DN (220, 221). Apoptosis of glomerular cells is 
supposed to be causally related to DN, as development of DN can completely be prevented by 
inhibiting apoptosis in the glomerulus (222).  
At the onset of DN, podocytes are key targets for glomerular injury (13-16). Podocytes loss 
occurs either by apoptosis or by detachment from the glomerular basement membrane (17). 
Hence, numbers of podocytes per glomerulus gradually decline in the course of DN (14) and 
this change is highly predictive of both progressive glomerular injury and long-term albumin 
excretion in diabetic patients (18). Thus, podocyte apoptosis seems to precede the 
development of DN and determines at least in part kidney function in diabetic patients.   
In contrast to other diabetic complications, only 20-40% of diabetic patients are susceptible to 
develop DN which seems to be genetically determined (33, 121). We recently identified a 
polymorphism in the signal sequence of the CNDP1 gene, encoding the serum carnosinase 
(CN-1), to be associated with susceptibility to DN. Since DN occurs significantly less 
frequent in diabetic patients that are homozygous for the shortest allelic form, i.e. (CTG)5 (the 
so-called CNDP1 Mannheim allele), the Mannheim-allele appears to be protective in terms of 
susceptibility to DN (44). This can be explained by the fact that the (CTG)5 allele corresponds 
with a low CN-1 secretion efficiency (168) and hence with a low serum CN-1 enzyme activity 
(44, 223). Because carnosine, the natural substrate for CN-1, has potential intrinsic renal 
protective properties (91, 94, 103, 104, 110) a low CN-1 expression or activity is beneficial 
for diabetic patients. Carnosine may prevent apoptosis (224-226) and up-regulates defensive 
mechanisms such as heat shock proteins (227).  
Short-term carnosine administration has been shown to protect against ischemia-reperfusion 
damage (99-101, 228, 229), and chronic oral carnosine administration can retard onset of 
diabetes in db/db mice (113). However, whether carnosine can protect against DN has not 
been investigated yet. In the present study we therefore tested the effect of oral carnosine 
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administration on early diabetic changes in STZ-induced diabetic rat kidneys, i.e. biochemical 
abnormalities, glomerular cell apoptosis and podocyte loss.  
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MATERIAL AND METHODS 
Animals and Diabetes Induction 
The study was performed in accordance with the ARVO statement for the use of animals in 
ophthalmic and vision research and the Regierungspräsidium Karlsruhe approved all animal 
procedures. Male Wistar rats (Harlan Laboratories, Inc.) were housed in a 12h light/dark cycle 
with free access to food and drinking water. Animals were randomly divided into three 
groups: 24 non-diabetic rats, 46 diabetic rats and 32 diabetic rats substituted with carnosine. 
Rats of the diabetic groups were rendered diabetic by intravenous injection of streptozotocin 
(45mg/kg, Roche, Mannheim, Germany) diluted in citrate buffer (pH 4.5). Animals were 
considered diabetic when blood glucose reached stable levels over 250 mg/dl. Insulin was 
occasionally given to individual diabetic rats to prevent critical weight loss. Metabolic data 
(body weight and blood glucose) were measured every week and blood samples for the 
determination of glycated haemoglobin concentration by affinity chromatography 
(MicromatII™; Bio-Rad Laboratories GmbH, Munich, Germany) were collected at the end of 
the study (n= 7-9 per group). All rats were sacrificed after 3 month of diabetes. Kidneys were 
taken out immediately and washed carefully in ice cold PBS. For immunohistochemistry, 
kidneys were subsequently fixed in 4% formalin. For western blot analysis, kidney cortex was 
isolated, washed thoroughly and frozen at -80°C until further processing.  
 
Carnosine Supplementation 
Diabetic Wistar rats were divided into two groups one week after diabetes induction. One 
diabetic control group, receiving pure water and a second diabetic group receiving water 
supplemented with 1 g of carnosine/kg body weight (Flamma S.p.a., Chignolo d’Isola, Italy). 
Carnosine was dissolved in the daily drinking volume. Water consumption and body weights 
of each cage were assessed once a week. L-carnosine–supplemented drinking water and 
lightproof bottles were replaced every day. Carnosine concentration in kidney tissue was 
measured fluorometically by high-performance liquid chromatography as previously 
described by Janssen (44) and Schonherr (186) et al.  
 
Renal histology 
2 micrometer kidney paraffin sections were stained with periodic acid–Schiff (PAS) and 
hematoxylin according to standard staining protocols. An investigator evaluated kidney 
histopathology in a blinded fashion and graded the glomerular damage including mesangial 
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matrix expansion, hyalinosis with focal adhesion, capillary dilation, glomerular tuft occlusion 
and sclerosis.  
Detection of glomerular cell apoptosis 
DNA strand breaks in apoptotic cells were visualized in 4 micrometer kidney paraffin 
sections using terminal transferase dUTP nick-end labelling (TUNEL, In Situ Cell Death 
Detection Kit, POD; Roche, Mannheim, Germany) according to the manufacturer’s 
instructions. In brief, sections were deparaffinised and treated with 2% H2O2 /Methanol to 
block endogenous peroxidase. Thereafter, slides were incubated with the TUNEL reaction 
mixture containing TdT and fluorescein d-UTP. After incubation, incorporated fluorescein 
was detected with an anti-fluorescein antibody conjugated with POD. Finally, the 
immuncomplexed POD was visualized by a substrate reaction using the DAB Peroxidase 
substrate kit (Vector Laboratories/ LINARIS Biologische Produkte GmbH, Wertheim, 
Germany), followed by nuclear counterstaining. TUNEL positive nuclei were counted in 10 
randomly selected kidney glomeruli per animal by two independent persons and their 
numbers were expressed relative to the corresponding glomerular area as assessed by an 
image analyzing system (CUE-2; Olympus Opticals, Hamburg, Germany). .  
 
Quantification of podocyte loss 
Paraffin-embedded, formalin-fixed, 3-µm-thick kidney sections were deparaffinised, treated 
with 2% H2O2 /methanol to block endogenous peroxidase, and microwaved at 500 W and 
270 W for 10 min each in citrate buffer.  The sections were then incubated with a polyclonal 
antibody to Wilms’ tumor 1 protein (Santa Cruz biotechnology Inc., Heidelberg, Germany) 
for 1 h at room temperature. After incubation with an appropriate POD coupled secondary 
antibody, POD was visualized by a substrate reaction using the DAB Peroxidase substrate kit 
(Vector Laboratories/ LINARIS Biologische Produkte GmbH, Wertheim, Germany), 
followed by nuclear counterstaining.  
Podocytes were identified according to cell shape, localization and positivity to wt-1 staining. 
Total numbers of podocytes were counted in kidney sections of randomly selected animals by 
two independent persons in 10 randomly selected kidney glomeruli per animal. The data are 
expressed as podocyte numbers relative to the corresponding glomerular area as assessed by 
an image analyzing system (CUE-2; Olympus Opticals, Hamburg, Germany). 
 
Western Blot   
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In order to isolate proteins from kidney cortex, frozen tissue was homogenized mechanically 
on ice. Proteins were extracted from lysates using a lysis buffer containing 125 mM NaCl, 10 
mM EDTA, 25 mM Hepes, 10 mM Na3VO4, 0.5 % deoxycholic acid, 0.1 % SDS, 1% Triton-
X-100, phosphatase-Inhibitor (Sigma, Steinheim, Germany) and Protease-Inhibitor (Roche, 
Mannheim, Germany). Insoluble debris was removed by centrifugation at 14.000g at 4°C for 
10 minutes. Protein extracts were heated in Laemmli-sample buffer (Bio-Rad Laboratories 
GmbH, Munich, Germany) for 5 min at 100°C prior to separation by SDS-PAGE. Thereafter, 
proteins were electrophoretically transferred to a PDVF membrane. Depending on the primary 
antibody applied, membranes were blocked with either 5 % skimmed milk or 5 % BSA in 
TBS according to the manufacturer’s recommendations. For detection of apoptosis signalling, 
antibodies against cytochrome c and Bax (Cell Signalling Technology, Danvers, USA) were 
utilized. Biochemical changes in the kidney were detected by antibodies directed against 
carboxymethyl-lysine- (CML, (230)), nitrotyrosine- (Alexis Biochemicals, Axxora 
Deutschland GmbH, Germany), methylglyoxal (methylglyoxal-H1, (231)) and N-
Acetylglucosamine-modified proteins (Abcam plc, Cambridge, United Kingdom). All 
antibodies were diluted and incubated as recommended by the manufacture. Immunoblots 
were made visible on Amersham Hyperfilms (Amersham, Buckinghamshire UK) by 
incubating the membranes with appropriate HRP-coupled secondary antibodies (Santa Cruz 
Biotechnology, Heidelberg, Germany) and by using enhanced chemiluminescence 
(PerkinElmer, LAS, USA). For loading control, membranes were stripped and re-probed with 
antibodies directed against GAPDH (GAPDH antibody - Loading Control, Abcam plc, 
Cambridge, United Kingdom). Intensity of the bands was measured by densitometry using the 
ImageJ 1.36b software. 
 
Statistical analysis 
All data are expressed as mean ± SD. Data analysis was performed by using unpaired two-
tailed student T-test and a P value less than 0.05 was considered as statistically significant.  
 
 




All diabetic rats developed stable hyperglycemia of more than >250 mg/dl two weeks after 
diabetes induction. Average blood glucose levels were significantly elevated in the diabetic 
rats (Fig. 1B; measurement at 3 month: non-diabetic vs. diabetic: 123 ± 36 mg/dl and 585 ± 
26 mg/dl; p<0.05 and non-diabetic vs. diabetic with carnosine: 123 ± 36 mg/dl and 592 ± 14 
mg/dl; p<0.05; diabetic vs. diabetic with carnosine not significant). The increase in body 
weight was significantly impaired after the onset of hyperglycemia resulting in reduced body 
weights at the end of the study (non-diabetic vs. diabetic: 457 ± 35 g and 282 ± 25 g; p<0.05 
and non-diabetic vs. diabetic with carnosine: 457 ± 35 g and 292 ± 38 g; p<0.05; diabetic vs. 
diabetic with carnosine not significant; Fig. 1A). Glycated haemoglobin levels were 2.3 fold 
increased in diabetic rats and 1.9 fold in diabetic rats supplemented with carnosine (non-
diabetic vs. diabetic: 5.9 ± 0.4 % and 13.4 ± 3.4 %; p<0.05 and non-diabetic vs. diabetic with 
carnosine: 5.9 ± 0.4 % and 11.2 ± 2.8; p<0.05; diabetic vs. diabetic with carnosine not 
significant; Fig. 1C). As depicted in Fig. 1D, carnosine levels were significantly decreased in 
diabetic kidneys (-98% compared to non-diabetic; non-diabetic vs. diabetic: 150.0 µg/g ± 3.5 
and 3.3 µg/g ± 0.7; p<0.05) two weeks after diabetes induction. In diabetic rats that were fed 
with carnosine, renal carnosine concentrations increased significantly (diabetic vs. diabetic 
with carnosine: 3.3 µg/g ± 0.7 and 300.0 µg/g ± 102.8; p<0.05) and were higher than in non-
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Fig. 1. The influence of oral carnosine treatment on STZ-induced hyperglycaemia and renal carnosine levels. 
Body weights (Panel A) and blood glucose levels (Panel B) of non-diabetic (NC, ●), diabetic (DC, □) and 
diabetic rats treated with carnosine (DC+C, ▲) were monitored over 12 weeks. In comparison to non-diabetic 
controls, all diabetic animals developed stable hyperglycemia and showed reduced body weights. Moreover, 
after 3 months levels of HbA1c were elevated in the diabetic animals. This was independent of carnosine 
treatment *=p<0.05 vs NC (Panel C). Measurement of renal carnosine by HPLC (Panel D) revealed that 
endogenous carnosine levels are reduced in diabetic animals and oral carnosine treatment increased renal 
carnosine levels above that of non diabetic controls *=p<0.05 vs NC, #=p<0.05 vs NC.  
 
Kidney histopathology was examined in PAS and hematoxylin stained kidney sections. Mild 
glomerulosclerotic changes, indicating an early and not advanced stage of a diabetic kidney 
damage, were found in the diabetic animals. No significant difference was found between the 






Fig. 2: Kidney histopathology. Kidney sections were stained with PAS and hematoxylin to evaluate the grade 
of the glomerular damage. The figure shows representative pictures of kidney section from non-diabetic (NC), 
diabetic (DC), and diabetic rats treated with carnosine (DC+C). In DC and DC+C a slight increase of 
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mesangial matrix and/or hyalinosis was evident. Conformable with an early stage of diabetic kidney damage, 
no further signs of glomerulosclerosis were found in DC and DC+C.  
 
 
To evaluate the effect of carnosine treatment on glomerular apoptosis, DNA strand breaks 
were assessed by in situ TUNEL staining. Three months after the onset of diabetes the 
numbers of TUNEL positive cells were significantly increased in non-treated diabetic rats 
(+32% compared to non-diabetics, non-diabetics: 0.0014 ± 0.0007 TUNEL+ cells/glomerular 
area and diabetics: 0.0019 ± 0.00018 TUNEL+ cells/glomerular area, p<0.05, Fig. 3A, B). In 
carnosine treated diabetic animals, the numbers of TUNEL positive cells were reduced by -
40% compared to diabetic animals (diabetics: 0.0019 ± 0.000018 TUNEL+ cells/glomerular 
area and diabetics with carnosine: 0.0013 ± 0.00007 TUNEL+ cells/glomerular area, p<0.05 
compared to diabetics, diabetics with carnosine vs. non-diabetics not significant, Fig. 3A, B). 
We further investigated the anti-apoptotic potential of carnosine by western blot analysis of 
kidney cortex lysates. Immunoblots stained for pro-apoptotic bax and cytochrome c displayed 
an increased expression of +175%, and +117% respectively in the diabetic kidneys of non-
treated rats (p<0.05 for both, Fig. 3C-F). Carnosine treatment significantly inhibited 
hyperglycemia-induced upregulation of bax (-63% compared to diabetics, p<0.05) and 
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Fig. 3: The influence of carnosine treatment on hyperglycemia-induced glomerular apoptosis. Apoptosis was 
tested by TUNEL staining and by western blot analysis using kidneys of non-diabetic (NC), diabetic (DC), and 
diabetic rats treated with carnosine (DC+C). A: Representative pictures of kidney sections stained by TUNEL. 
Arrows indicate cells counted as TUNEL positive. Original magnification 400x. B: Quantification of TUNEL 
positive cells was performed in a blinded fashion on ten randomly selected glomeruli per animal (n=4, for 
each group) by two independent investigators. Results are expressed as mean TUNEL positive 
cells/glomerular area ± SD. Note that there is no significant difference (n.s.) in the proportion of TUNEL 
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positive cells in NC vs. DC+C, but a significant increase in DC. *=p<0.05 compared to non-diabetic controls 
and #=p<0.05 compared to diabetics. C, E: Representative immunoblots stained with antibodies directed 
against bax and cytochrome c, respectively. Antibodies directed against GAPDH were used to control for 
equal loading. D, F: Quantification of bax and cytochrome c protein expression by densitometry 
measurement of immunoreactive bands. A total of 5-6 animals per group were evaluated. Ratios of 
bax/GAPDH or cytochrome c/GAPDH were calculated to avoid loading dissimilarity errors. Results are 
expressed as mean ration ± SD relative to NC. *=p<0.05 compared to non-diabetic controls and #=p<0.05 
compared to diabetics. 
 
 
To investigate whether carnosine treatment can prevent podocyte loss in diabetic rats, we 
determined glomerular podocyte numbers using wt-1 as podocyte marker in histological 
kidney sections. Podocytes numbers were significantly reduced in diabetic kidneys (-21% 
compared to non-diabetics, non-diabetics: 0.0018 ± 0.00023 WT-1+ cells/glomerular area and 
diabetics: 0.0014 ± 0.00018 WT-1+ cells/glomerular area, p<0.05, Fig. 4A, B), while in 
diabetic rats fed with carnosine, podocyte numbers were normalized (+23% compared to 
diabetics, diabetics: 0.0014 ± 0.00018 WT-1+ cells/glomerular area and diabetic with 
carnosine: 0.0017 ± 0.00022 WT-1+ cells/glomerular area, p<0.05 and -4% compared to non-















Fig. 4 The influence of carnosine treatment on diabetic podocyte loss. Podocytes were stained with antibodies 
directed against wt-1 in kidney sections of non-diabetic (NC), diabetic (DC), and carnosine treated diabetic 
(DC+C) rats. A: Representative pictures of kidney sections stained for wt-1. Arrows indicate wt-1 positive 
cells. Original magnification 400x Panel B: Quantification of wt-1 positive cells was performed in a blinded 
fashion on ten randomly selected glomeruli per animal (n=4, for each group) by two independent 
investigators. Results are expressed as mean podocyte numbers relative to the corresponding glomerular area 
± SD. No significant difference (n.s.) in podocyte numbers were found between NC and DC+C, whereas 
podocyte numbers were significantly reduced in DC. *=p<0.05 compared to non-diabetic controls and 
#=p<0.05 compared to diabetics 
 
To examine the influence of carnosine on the biochemical abnormalities induced by diabetes, 
the activity of three cells damaging mechanisms investigated by western blotting. To this end, 
antibodies directed against nitrosylated (NT, Fig. 5A) and carboxymethyl-lysine (CML, Fig. 
5C) -modified proteins as markers of oxidative stress were used. Moreover, immunoblots 
were incubated with antibodies directed against methylglyoxal-  (MG, Fig. 5E) and GlcNAc-
modified proteins (Fig. 5G) in order to assess AGE-production and the activity of the 
hexosamine pathway. In diabetic kidney cortex, the levels of NT- (Fig. 5B) and of CML- 
(Fig. 5D) modified proteins were significantly increased (+ 167% and +88%, respectively, 
p<0.05 for both compared to non-diabetics). Likewise, the levels of MG- and GlcNAc-
modified proteins were increased in diabetic kidney lysates (+250% and +326%, respectively 
compared to non-diabetics, p<0.05, Fig 5F and H). Carnosine treatment of diabetic rats had no 
effect on hyperglycemia-induced increase in NT-, CML-, MG- and N-Acetylglucosamine-
protein levels (diabetic with carnosine vs. non-diabetics: +204% for NT, +122% for CML, 
+333% for MG and +230%, all p<0.05 compared to non-diabetics, diabetics with carnosine 
vs. diabetics not significant).   
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FIGURE 5  
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Fig. 5. The effect of carnosine treatment on oxidative stress, AGE formation and activity of the hexosamine 
pathway in diabetic kidney cortex. In order to assess the effect of carnosine treatment on hyperglycemia-
induced biochemical changes, kidney cortex lysates from non-diabetic (NC), diabetic (DC), and diabetic rats 
treated with carnosine (DC+C) were probed with antibodies against nitrotyrosine- (NT, Fig. 4A, B) and 
carboxymethyl-lysine- (CML, Fig. 4C, D) modified proteins as markers of oxidative stress, methylglyoxal- 
(MG, Fig. 4E, F) modified proteins as a marker for AGE-production and N-acetyl-D-glucosamine- (GlcNAc, 
Fig. 4G, H) modified proteins as a marker for hexosamine pathway activation. Representative immunoblots 
(Fig. 4A, C, E, G) and corresponding densitometric quantifications (Fig. 4B, D, F, H) show a significant 
increase of all the markers in diabetic kidneys, irrespective of carnosine treatment. Ratios between the 
different biochemical markers and GAPDH were assessed to avoid loading dissimilarity errors. A total of 3 
animals per group were evaluated for each marker. Results are expressed as mean ratio ± SD. *=p<0.05 


















Experimental evidence suggests that the carnosine- carnosinase system might play an 
important role in diabetes associated complications, in particular in DN (44, 113). Diabetic 
patients that are homozygous for the Mannheim allele (CTG)5 are less affected by DN. This 
genotype is associated with a low serum CN-1 activity, most likely because the (CTG)5 repeat 
in the signal peptide of CN-1 influences CN-1 secretion (18). Inasmuch as individuals 
homozygous for the Mannheim allele develop less frequently DN, it is conceivable that the 
protective effect of the Mannheim allele is directly related to the amount of CN-1 found in 
serum.  
A number of studies conducted in recent years have suggested that carnosine, the substrate of 
CN-1, might be beneficial in relation to diabetic complications diabetes (44, 91, 112, 113). 
Hence, a low carnosine turnover in (CTG)5 homozygous patients could be a plausible 
explanation why these patients develop less frequently DN. Yet, definitive proof for the 
salutary effect of carnosine in terms of preventing hyperglycaemia mediated damage in renal 
tissue is still lacking. In the present study, we therefore investigated whether oral carnosine 
treatment can ameliorate early changes in kidneys of streptozotocin-induced diabetic rats. The 
main findings of this study are the following. Carnosine treatment prevents the up-regulation 
of pro-apoptotic molecules in the kidneys of diabetic rats. It also prevented podocyte loss in 
these rats. This is independent of major biochemical abnormalities that occur as a 
consequence of diabetes, since carnosine did not influence NT, CML, methylglyoxal or 
GlcNAc expression in kidneys of diabetic rats.   
 
Microvascular complications in diabetic patients are for a great deal causally related to an 
increased production of ROS, AGEs and GlcNAc-modified proteins, evoked by chronic 
hyperglycemia. Based on the intrinsic biochemical properties of carnosine, i.e. antioxidant 
effects and inhibition of AGE formation (91-96), we expected that carnosine feeding would 
counteract these factors in kidneys of diabetic rats. Yet surprisingly, our results clearly show 
that carnosine feeding of diabetic rats is neither capable of preventing oxidative stress and 
AGE formation, nor could carnosine prevent the activation of the hexosamine pathway in our 
experimental setting, despite of carnosine feeding significantly increased renal carnosine 
concentrations. However, it is wise to take some caution in stating that carnosine has 
antioxidant activity, as most of the data that support this assumption are derived from in vitro 
cell culture studies (232, 233).  Similar to our findings, Aruoma et al (232) have questioned 
the anti-oxidative property of carnosine in vivo and they concluded from their study that it is 
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possible that carnosine could act as physiological antioxidant by scavenging hydroxyl 
radicals, but it does not have a broad spectrum of antioxidant activity, and its ability to inhibit 
lipid peroxidation is not well established. 
Similarly, the ability of carnosine to inhibit AGE formation was mostly demonstrated in in 
vitro experiments. Nonetheless, it has been repeatedly shown that carnosine is protective in 
models of ischemia reperfusion (99-101, 228, 229). In terms of oxidative challenge, these 
models clearly differ from the diabetic model where sustained severe hyperglycemia over a 
period of 3 months may yield a higher oxidative burden compared to a relative short period of 
ischemia. It might well be that the protective biochemical characteristics of carnosine to 
counteract oxidative stress and hyperglycemia-induced protein modification in the diabetic 
kidney are exhausted by severity and duration of experimental diabetes. Besides, it has to be 
admitted that the antioxidant and AGE inhibiting capacity of carnosine can still be sufficient 
to protect the glomerular capillaries the surrounding parenchymal cells. Such a localized 
effect would be bound to go unnoticed in western blot analysis.  
 
Nonetheless, this study does show that carnosine has a cell protective effect in the context of 
diabetes, as apoptosis of glomerular cells and podocyte loss were significantly diminished by 
carnosine. Since carnosine is a multifunctional dipeptide involved in numerous physiological 
processes, e.g. pH buffering (234, 235), enzyme regulation (75), and induction of heat shock 
proteins (227), these properties may equally contribute to the cytoprotective effect of 
carnosine. 
 
Hyperglycaemia causes mitochondrial stress, an eligible condition for the induction of 
apoptosis. Apoptosis is believed to play an important role in a number of glomerular diseases 
including DN (236), and is most likely caused by changing the balance in the expression of 
the anti- and pro-apoptotic molecules Bcl-2 and Bax respectively. While Bcl-2 expression 
may account for maintaining glomerular hypercellularity, Bax expression might be more 
important in cell loss leading to glomerulosclerosis.  Bax forms oligomers thereby increasing 
mitochondrial permeability and facilitating the release of cytochrome c from the 
mitochondrial intermembrane space. Once released from the mitochondria, cytochrome c 
further activates apoptosis. In our model both bax as well as cytochrome c expression were 
increased in the cortex of diabetic rats, pointing out that pro-apoptotic signalling is active in 
the diabetic kidneys. In line with this observation, quantification of TUNEL stained kidney 
sections revealed increased glomerular apoptosis in diabetic rats. This shift towards apoptosis 
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was restrained by carnosine treatment, indicating a cytoprotective effect of carnosine on 
glomerular cells. Recently, Isermann et al. demonstrated that DN can be prevented by 
protecting glomerular endothelial cells and podocytes against apoptosis (222). Interestingly, 
carnosine showed similar effects as reported for activated protein C in the study of Iserman et 
al., in that both molecules down-regulated bax and cytochrome c and reduced TUNEL 
positive cells in diabetic animals.  
 
The increase in glomerular apoptosis, and in parallel podocyte loss, in diabetic kidneys was 
significantly ameliorated by carnosine treatment. Although this study did not address the 
exact identity of the glomerular apoptotic cells, it is likely that part of these cells were of 
podocyte origin, as podocyte loss and glomerular cell apoptosis coincided. In human disease 
and in experimental models podocyte loss has been linked to the development of proteinuria 
and glomerulosclerosis (237) and is predictive for the progression of DN (18, 238-240). In 
keeping with the central role of podocytes in the glomerular architecture and the beneficial 
effect of carnosine treatment on podocyte loss, our results may indicate that carnosine could 
protect from DN. Moreover, the clear pro- and anti-apoptotic effect that we have observed in 
western blot analysis might not represent changes limited to the glomerulus and cells situated 
in areas outside of the glomerulus might also be protected by carnosine. Therefore, carnosine 
could have a broader therapeutic spectrum that goes beyond the salutary effect demonstrated 
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